• DESCRIPTION OF THE DETECTION SYSTEM

      CLART® HPV2 enables to detect infections and coinfections of the 35 most clinically relevant types of Human Papillomavirus (HPV) (6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 68, 70, 71, 72, 73, 81, 82, 83, 84, 85 and 89). As starting material, the following different types of human samples may be used: swabs, cell suspensions and formalin-fixed paraffin-embedded tissue.

      Detection is based on our CLART® technology: PCR amplification of a fragment of the viral region L1, followed by visualization in low-density microarray. The chosen sequence is highly conserved in all HPV types, while at the same time displays enough variations among HPV types so as to distinguish each type by means of specific probes.

      Basically, PCR amplified products labelled with biotin, hybridize with their specific complementary probes immobilised in well-defined areas of the microarray. Subsequent incubation steps take place thereon: first, with a streptavidin-peroxidase conjugate, and second, with an o-dianisidine substrate.

      A non-soluble product precipitates thereafter in regions of the microarray where specific hybridization between an amplified product and their specific probes has taken place.

      Thereafter, analysis and interpretation of results are automatically performed by GENOMICA’s reader (CAR® or CLINICAL ARRAY READER), running tailor-made software. Autoclart® plus may alternatively be used.

1- DEVICE DESCRIPTION CLART HPV2
2- HPV2 Brochure
3- Manual of CLART HPV2 HPV2L V17 Feb 2017 English